Literature DB >> 7086148

Isolation of human C-reactive protein and serum amyloid P component.

F C De Beer, M B Pepys.   

Abstract

Procedures are described for the isolation in high yield of consistent, highly purified preparations of human C-reactive protein (CRP) and serum amyloid P component (SAP). CRP was obtained from malignant ascitic and pleural fluids by calcium-dependent affinity chromatography on pneumococcal C-polysaccharide covalently coupled to cyanogen bromide-activated Sepharose. It was then gel filtered on Ultrogel AcA44 (acrylamide-agarose beads) in the presence of calcium ions, combining molecular sieve chromatography with removal of contaminating SAP by its affinity of agarose. Residual trace contaminants were removed by immunoabsorption with anti-normal human serum and anti-SAP antibodies insolubilised on Sepharose and/or by absorption with Sepharose-Con A to remove glycoproteins and Blue-Sepharose to remove albumin. After a final gel filtration step on Sephacryl S-300 35-45% of the initial CRP was recovered in pure form according to biochemical and immunochemical criteria. SAP was isolated from normal serum by calcium-dependent affinity chromatography on unsubstituted Sepharose beads, followed by solid-phase immunoabsorption of contaminants and finally gel filtration on Sephacryl S-300. At least 50% of the SAP in the starting material was recovered in pure form according to biochemical and immunochemical criteria. Ready availability of such preparations facilitates biochemical, biophysical and particularly biological studies of these plasma proteins.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086148     DOI: 10.1016/0022-1759(82)90300-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  50 in total

1.  Inhibition of fibrocyte differentiation by serum amyloid P.

Authors:  Darrell Pilling; Christopher D Buckley; Mike Salmon; Richard H Gomer
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Examining serum amyloid P component microheterogeneity using capillary isoelectric focusing and MALDI-MS.

Authors:  Noah G Weiss; Jason W Jarvis; Randall W Nelson; Mark A Hayes
Journal:  Proteomics       Date:  2010-12-01       Impact factor: 3.984

3.  Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Authors:  Simon E Kolstoe; Basil H Ridha; Vittorio Bellotti; Nan Wang; Carol V Robinson; Sebastian J Crutch; Geoffrey Keir; Riitta Kukkastenvehmas; J Ruth Gallimore; Winston L Hutchinson; Philip N Hawkins; Stephen P Wood; Martin N Rossor; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

4.  A primed state exists in vivo following histological regression of amyloidosis.

Authors:  P N Hawkins; M B Pepys
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease.

Authors:  J Stuart; P C Stone; N O Akinola; J R Gallimore; M B Pepys
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

6.  Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli.

Authors:  M B Pepys; S E Booth; G A Tennent; P J Butler; D G Williams
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

7.  C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer.

Authors:  Azubuike I Okemefuna; Lasse Stach; Sudeep Rana; Akim J Ziai Buetas; Jayesh Gor; Stephen J Perkins
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

8.  C-reactive protein and apoB containing lipoproteins are associated with Mycobacterium leprae in lesions of human leprosy.

Authors:  M J Ridley; D S Ridley; F C De Beer; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

9.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.